Practical info

Upcoming programme edition

Date(s):
5 modules of 2 or 3 days:
Strategy - 11 & 17 October 2017 - 1695 euros (excl. 21% VAT)
Operations - 22 November & 5 December 2017 - 1695 euros (excl. 21% VAT)
Finance - 7, 21 & 27 February 2018 - 2295 euros (excl. 21% VAT)
Accounting - 22 March, 19 & 26 April 2018 - 2295 euros (excl. 21% VAT)
People - 16 & 23 May 2018 - 1695 euros (excl. 21% VAT)

Length:
12 days

Venue(s):
Vlerick Campus Leuven , Vlerick Campus Ghent

Language:
Dutch

Fee:
7095 euros (excl. 21% VAT)
All modules

Financial Benefits

Enrol

Drive real change in your organisation

A learning experience with real impact on your operations? A management programme tailored to the specific needs of your business? Contact us and discover how we can design and deliver customised programmes for your team that add genuine value to your organisation.

Need help?

Contact our Programme Advisor
Programme Advisor
Tel + 32 9 210 98 84
programmeadvisor@vlerick.com
Find the programme most relevant for you!

Our programme finder allows you to find the management programme that best fits your needs.

Find a Programme

Meet Us

Info Sessions & Open Days
09 May
Drop In on our Ghent Campus
Category: General Info Sessions

01 Jun
MBA Info Session in Moscow
Category: General Info Sessions

02 Jun
Drop In on our Brussels Campus
Category: General Info Sessions

Our approach to learning

It’s all about you and your company’s challenges at Vlerick Business School. Discover our unique approach to learning!

Vlerick expertise in Healthcare Management

  1. Pharma and data as gospel

    Developing drugs is a time-consuming process. In order to speed it up, the Belgian biopharmaceuticals producer UCB has decided to switch to a data-driven organisation. It was necessary to ‘convert’ the entire company to achieve this, says CIO Herman De Prins.
  2. Innovative cancer treatments: how much are we willing to pay?

    One man in three and one woman in four will develop cancer before their 75th birthday. In Belgium, cancer is the second major cause of disease burden after cardiovascular diseases and it is unlikely this will change in the foreseeable future. Increasingly better but more expensive cancer therapies are becoming available. Needless to say, in these times of austerity, the public budget for cancer treatment is under pressure. How can we ensure all patients continue to have access to these expensive but potentially life-saving medicines at a price society can afford, while at the same time encouraging pharmaceutical companies to innovate?
All articles